Back to Agenda
SESSION 4: Sample Management
Session Chair(s)
Neveen Kamel
Regulatory Affairs Head North Africa, Egypt & French-speaking Africa, Merck Group, Egypt
Zainab Aziz, MSc, RPh
Associate Director- Regulatory Policy MEA, Novartis, South Africa
Overview: This session will explore challenges associated with sample provision for Post-Approval Changes and promote best practices in Sample Management, leveraging Reliance pathways. The session will also highlight the development of a unified laboratory framework for sample testing through the Network of African Reliance Laboratories (NARL), the growing importance of post-marketing surveillance, share effective risk management strategies for product release post-importation and emphasise capacity building for local laboratories to detect substandard and falsified medicines.
Speaker(s)
Streamlining Sample Management to Strengthen Health Outcomes in Africa
Zainab Aziz, MSc, RPh
Associate Director- Regulatory Policy MEA, Novartis, South Africa
Reliance Frees up Capacity for Efficient Post-Marketing Surveillance of Medicines
Joerg Garbe, PhD, MSc
IFPMA In-Country Testing Taskforce Lead; Global Quality Manager & Policy Lead, F. Hoffmann-La Roche Ltd, Switzerland
Sample Management in the Context of Reliance for NDA and PACs
Neven Ahmed
Reliance team leader, Egyptian Drug Authority (EDA), Egypt
Sample Management overview – Qatar Experience
Noha Mohamed Reda Arram
Head of Drug Quality Control Laboratory - Pharmacy & Drug Control Department, Ministry of Public Health (MOPH), Qatar, Qatar
Panel Discussion with Q&A (With the additional participation of):
Assane Coulibaly
CEO / Director General, Autorité Ivoirienne de Régulation Pharmaceutique (AIRP) / Ivorian Pharm RA, Côte d'Ivoire
Have an account?